Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women.

Gutiérrez-Malacatt H, Ayala-Sanchez M, Aquino-Ortega X, Dominguez-Rodriguez J, Martinez-Tovar A, Olarte-Carrillo I, Martinez-Hernandez A, C CC, Orozco L, Cordova EJ.

Asian Pac J Cancer Prev. 2016;17(4):2265-70.

2.

Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding.

Dzikiewicz-Krawczyk A, Macieja A, Mały E, Januszkiewicz-Lewandowska D, Mosor M, Fichna M, Strauss E, Nowak J.

J Hematol Oncol. 2014 Jun 2;7:43. doi: 10.1186/1756-8722-7-43.

3.

A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.

Kazmi HR, Chandra A, Kumar S, Satyam LK, Gupta A, Nigam J, Srivastava M, Mittal B.

J Cancer Res Clin Oncol. 2016 Dec;142(12):2577-2583. Epub 2016 Sep 12.

PMID:
27620744
4.

Significance of ATM Gene Polymorphisms in Chronic Myeloid Leukemia - a Case Control Study from India.

Gorre M, Mohandas PE, Kagita S, Cingeetham A, Vuree S, Jarjapu S, Nanchari S, Meka PB, Annamaneni S, Dunna NR, Digumarti R, Satti V.

Asian Pac J Cancer Prev. 2016;17(2):815-21.

5.

No evidence for genetic association with the let-7 microRNA-binding site or other common KRAS variants in risk of endometriosis.

Luong HT, Nyholt DR, Painter JN, Chapman B, Kennedy S, Treloar SA, Zondervan KT, Montgomery GW.

Hum Reprod. 2012 Dec;27(12):3616-21. doi: 10.1093/humrep/des329. Epub 2012 Sep 25.

6.

MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.

Liu YC, Hsiao HH, Yang WC, Liu TC, Chang CS, Yang MY, Lin PM, Hsu JF, Lee CP, Lin SF.

Mol Carcinog. 2014 Dec;53(12):951-9. doi: 10.1002/mc.22061. Epub 2013 Jul 2.

PMID:
23818300
7.

KRAS and VEGF gene 3'-UTR single nucleotide polymorphisms predicted susceptibility in colorectal cancer.

Yang M, Xiao X, Xing X, Li X, Xia T, Long H.

PLoS One. 2017 Mar 22;12(3):e0174140. doi: 10.1371/journal.pone.0174140. eCollection 2017.

8.

MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.

Schneiderova M, Naccarati A, Pardini B, Rosa F, Gaetano CD, Jiraskova K, Opattova A, Levy M, Veskrna K, Veskrnova V, Buchler T, Landi S, Vodicka P, Vymetalkova V.

Mutagenesis. 2017 Oct 17;32(5):533-542. doi: 10.1093/mutage/gex026.

PMID:
29048575
9.

Evaluation of genetic variants in microRNA biosynthesis genes and risk of breast cancer in Chinese women.

Jiang Y, Chen J, Wu J, Hu Z, Qin Z, Liu X, Guan X, Wang Y, Han J, Jiang T, Jin G, Zhang M, Ma H, Wang S, Shen H.

Int J Cancer. 2013 Nov;133(9):2216-24. doi: 10.1002/ijc.28237. Epub 2013 Jul 11.

10.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N.

Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10.

11.

The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.

Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D; BCFR Investigators, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, Dörk T, Dürst M, Eccles DM, Ekici AB, Easton D; EMBRACE Investigators, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O; GEMO Study Collaborators, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M; HEBON Investigators, Heikkinen T, Hein R, Høgdall C, Høgdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G; kConFab Investigators and the Consortium of Investigators of Modifiers of BRCA1/2, Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, Lapolla JP, Lázaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Lindblom A; SWE-BRCA Investigators, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA; Ovarian Cancer Association Consortium.

Clin Cancer Res. 2011 Jun 1;17(11):3742-50. doi: 10.1158/1078-0432.CCR-10-3405. Epub 2011 Mar 8.

12.

Single nucleotide polymorphisms of multidrug resistance gene 1 (MDR1) and risk of chronic myeloid leukemia.

Yaya K, Hind D, Meryem Q, Asma Q, Said B, Sellama N.

Tumour Biol. 2014 Nov;35(11):10969-75. doi: 10.1007/s13277-014-2400-4. Epub 2014 Aug 5.

PMID:
25087925
13.

Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.

Huang X, Yang Y, Guo Y, Cao ZL, Cui ZW, Hu TC, Gao LB.

Genet Mol Res. 2015 Dec 14;14(4):16913-20. doi: 10.4238/2015.December.14.19.

14.

Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.

Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB.

Breast Cancer Res Treat. 2011 Jul;128(1):79-84. doi: 10.1007/s10549-010-1080-z. Epub 2010 Jul 30.

15.

Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels.

Crowley EH, Arena S, Lamba S, Di Nicolantonio F, Bardelli A.

Hum Mutat. 2014 Feb;35(2):208-14. doi: 10.1002/humu.22487. Epub 2013 Dec 27.

PMID:
24282149
16.

Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia.

Kim DH, Xu W, Ma C, Liu X, Siminovitch K, Messner HA, Lipton JH.

Blood. 2009 Mar 12;113(11):2517-25. doi: 10.1182/blood-2008-07-169110. Epub 2009 Jan 13.

17.

A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD.

Hu H, Zhang L, Teng G, Wu Y, Chen Y.

Int J Chron Obstruct Pulmon Dis. 2015 Aug 17;10:1641-9. doi: 10.2147/COPD.S83596. eCollection 2015.

18.

A variant at a potentially functional microRNA-binding site in BRIP1 was associated with risk of squamous cell carcinoma of the head and neck.

Liu H, Gao F, Dahlstrom KR, Li G, Sturgis EM, Zevallos JP, Wei Q, Liu Z.

Tumour Biol. 2016 Jun;37(6):8057-66. doi: 10.1007/s13277-015-4682-6. Epub 2015 Dec 28.

19.

Single nucleotide polymorphisms within MicroRNAs, MicroRNA targets, and MicroRNA biogenesis genes and their impact on colorectal cancer survival.

Mullany LE, Herrick JS, Wolff RK, Slattery ML.

Genes Chromosomes Cancer. 2017 Apr;56(4):285-295. doi: 10.1002/gcc.22434. Epub 2017 Jan 25.

Supplemental Content

Support Center